Opus Genetics Revenue vs. Net Income
| IRD Stock | 2.08 0.05 2.35% |
Total Revenue | First Reported 2010-12-31 | Previous Quarter 12.6 M | Current Value 15.5 M | Quarterly Volatility 10.9 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.8 | 0.9 |
|
|
For Opus Genetics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Opus Genetics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Opus Genetics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Opus Genetics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Opus Genetics over time as well as its relative position and ranking within its peers.
Check out Risk vs Return Analysis. Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opus Genetics. If investors know Opus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opus Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.86) | Revenue Per Share | Quarterly Revenue Growth (0.20) | Return On Assets | Return On Equity |
The market value of Opus Genetics is measured differently than its book value, which is the value of Opus that is recorded on the company's balance sheet. Investors also form their own opinion of Opus Genetics' value that differs from its market value or its book value, called intrinsic value, which is Opus Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opus Genetics' market value can be influenced by many factors that don't directly affect Opus Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opus Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opus Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Opus Genetics Net Income vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Opus Genetics's current stock value. Our valuation model uses many indicators to compare Opus Genetics value to that of its competitors to determine the firm's financial worth. Opus Genetics is rated fourth overall in revenue category among its peers. It is rated fifth overall in net income category among its peers . At present, Opus Genetics' Total Revenue is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Opus Genetics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Opus Revenue vs. Competition
Opus Genetics is rated fourth overall in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 229.66 Million. Opus Genetics holds roughly 10.99 Million in revenue claiming about 5% of equities under Health Care industry.
Opus Net Income vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Opus Genetics |
| = | 10.99 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Opus Genetics |
| = | (57.53 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Opus Net Income Comparison
Opus Genetics is currently under evaluation in net income category among its peers.
Opus Genetics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Opus Genetics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Opus Genetics will eventually generate negative long term returns. The profitability progress is the general direction of Opus Genetics' change in net profit over the period of time. It can combine multiple indicators of Opus Genetics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -55.9 M | -53.1 M | |
| Income Before Tax | -51.8 M | -49.2 M | |
| Total Other Income Expense Net | 5.2 M | 5.5 M | |
| Net Loss | -51.8 M | -49.2 M | |
| Net Loss | -51.8 M | -49.2 M | |
| Income Tax Expense | 10.8 K | 10.3 K | |
| Net Loss | (1.94) | (2.04) | |
| Income Quality | 0.51 | 0.47 | |
| Net Income Per E B T | 0.90 | 0.79 |
Opus Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Opus Genetics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Opus Genetics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Opus Genetics' important profitability drivers and their relationship over time.
Opus Genetics Earnings Estimation Breakdown
The calculation of Opus Genetics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Opus Genetics is estimated to be -0.108325 with the future projection ranging from a low of -0.1425 to a high of -0.0875. Please be aware that this consensus of annual earnings estimates for Opus Genetics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.14 Lowest | Expected EPS | -0.09 Highest |
Opus Genetics Earnings Projection Consensus
Suppose the current estimates of Opus Genetics' value are higher than the current market price of the Opus Genetics stock. In this case, investors may conclude that Opus Genetics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Opus Genetics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 10 | 31.24% | 0.0 | -0.108325 | -1.86 |
Opus Genetics Earnings per Share Projection vs Actual
Actual Earning per Share of Opus Genetics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Opus Genetics predict the company's earnings will be in the future. The higher the earnings per share of Opus Genetics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Opus Genetics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Opus Genetics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Opus Genetics should always be considered in relation to other companies to make a more educated investment decision.Opus Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Opus Genetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-11-12 | 2025-09-30 | -0.132 | -0.25 | -0.118 | 89 | ||
2025-08-13 | 2025-06-30 | -0.19 | -0.12 | 0.07 | 36 | ||
2025-05-08 | 2025-03-31 | -0.205 | -1.1128 | -0.9078 | 442 | ||
2025-03-31 | 2024-12-31 | -0.0475 | -1.27 | -1.2225 | 2573 | ||
2024-11-11 | 2024-09-30 | -0.25 | -0.2879 | -0.0379 | 15 | ||
2024-08-13 | 2024-06-30 | -0.24 | -0.3 | -0.06 | 25 | ||
2024-05-10 | 2024-03-31 | -0.29 | -0.29 | 0.0 | 0 | ||
2024-03-08 | 2023-12-31 | -0.05 | -0.21 | -0.16 | 320 | ||
2023-11-13 | 2023-09-30 | -0.22 | 0.25 | 0.47 | 213 | ||
2023-08-11 | 2023-06-30 | -0.23 | -0.24 | -0.01 | 4 | ||
2023-05-15 | 2023-03-31 | -0.16 | -0.28 | -0.12 | 75 | ||
2023-03-30 | 2022-12-31 | 1.58 | 1.58 | 0.0 | 0 | ||
2022-11-04 | 2022-09-30 | -0.22 | -0.22 | 0.0 | 0 | ||
2022-08-12 | 2022-06-30 | -0.25 | -0.25 | 0.0 | 0 | ||
2022-05-13 | 2022-03-31 | -0.35 | -0.35 | 0.0 | 0 | ||
2022-03-24 | 2021-12-31 | -0.35 | -0.35 | 0.0 | 0 | ||
2021-11-12 | 2021-09-30 | -0.25 | -0.25 | 0.0 | 0 | ||
2021-08-12 | 2021-06-30 | -0.52 | -0.52 | 0.0 | 0 | ||
2021-05-07 | 2021-03-31 | -3.57 | -3.57 | 0.0 | 0 | ||
2021-03-10 | 2020-12-31 | -4.7 | -4.7 | 0.0 | 0 | ||
2020-11-04 | 2020-09-30 | -0.33 | -0.33 | 0.0 | 0 | ||
2020-08-10 | 2020-06-30 | -0.62 | -2.5 | -1.88 | 303 | ||
2020-05-18 | 2020-03-31 | -0.15 | -0.58 | -0.43 | 286 | ||
2020-03-16 | 2019-12-31 | -2 | -1.86 | 0.14 | 7 | ||
2019-12-27 | 2019-09-30 | -1.96 | -1.96 | 0.0 | 0 | ||
2019-08-07 | 2019-06-30 | -2.44 | -2.44 | 0.0 | 0 | ||
2019-05-13 | 2019-03-31 | -0.93 | -4.07 | -3.14 | 337 | ||
2019-03-08 | 2018-12-31 | -0.09 | -4.32 | -4.23 | 4700 | ||
2018-11-05 | 2018-09-30 | -0.17 | -8.16 | -7.99 | 4700 | ||
2018-08-06 | 2018-06-30 | -0.17 | -5.76 | -5.59 | 3288 | ||
2018-05-07 | 2018-03-31 | -0.14 | -3.36 | -3.22 | 2300 | ||
2018-03-13 | 2017-12-31 | -0.14 | -5.76 | -5.62 | 4014 | ||
2017-11-06 | 2017-09-30 | -10.24 | -1.92 | 8.32 | 81 | ||
2017-08-07 | 2017-06-30 | -10.08 | 1.92 | 12.0 | 119 | ||
2017-05-05 | 2017-03-31 | -8 | -43.2 | -35.2 | 440 |
Use Opus Genetics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Opus Genetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Opus Genetics will appreciate offsetting losses from the drop in the long position's value.Opus Genetics Pair Trading
Opus Genetics Pair Trading Analysis
The ability to find closely correlated positions to Opus Genetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Opus Genetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Opus Genetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Opus Genetics to buy it.
The correlation of Opus Genetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Opus Genetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Opus Genetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Opus Genetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Opus Genetics position
In addition to having Opus Genetics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Alternative Currency ETFs Thematic Idea Now
Alternative Currency ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Alternative Currency ETFs theme has 102 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alternative Currency ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
To fully project Opus Genetics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Opus Genetics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Opus Genetics' income statement, its balance sheet, and the statement of cash flows.